Аннотация
The possibility of glioblastoma virotherapy at intravenous injection of the LIVP–GFP recombinant virus was studied in experimental model of orthotopic xenotransplantation of human glioblastoma cell line U87 to SCID laboratory mice. The LIVP–GFP recombinant virus deficient for thymidine kinase exhibited a significantly greater oncolytic capacity than the original LIVP virus, and an intravenous injection of LIVP–GFP at the early stages of tumorigenesis in mouse brain in most cases resulted in the lysis of the tumor.
Язык оригинала | английский |
---|---|
Страницы (с-по) | 30-33 |
Число страниц | 4 |
Журнал | Doklady Biochemistry and Biophysics |
Том | 478 |
Номер выпуска | 1 |
DOI | |
Состояние | Опубликовано - 1 янв 2018 |